Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225. https://doi.org/10.1042/BSR20150089.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diamantis N, Banerji U. Antibody-drug conjugates—an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362–7. https://doi.org/10.1038/bjc.2015.435.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggarwal D, Yang J, Salam MA, Sengupta S, Al-Amin MY, Mustafa S, Khan MA, Huang X, Pawar JS. Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy. Front Immunol. 2023;14:1203073. https://doi.org/10.3389/fimmu.2023.1203073.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Z, Li S, Han S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Sig Transduct Target Ther. 2022;7(1):93. https://doi.org/10.1038/s41392-022-00947-7.

Article  CAS  Google Scholar 

Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug conjugates for cancer therapy. Molecules. 2020;25:4764. https://doi.org/10.3390/molecules25204764.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sasso JM, Tenchov R, Bird R, Iyer KA, Ralhan K, Rodriguez Y, Zhou QA. The evolving landscape of antibody-drug conjugates: in depth analysis of recent research progress. Bioconjug Chem. 2023;34(11):1951–2000. https://doi.org/10.1021/acs.bioconjchem.3c00374.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ. Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload. Pharmaceutics. 2023;15(8):2160. https://doi.org/10.3390/pharmaceutics15082160.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165–82. https://doi.org/10.3322/caac.21705.

Article  PubMed  Google Scholar 

Sun T, Niu X, He Q, Liu M, Qiao S, Qi RQ. Development, efficacy and side effects of antibody-drug conjugates for cancer therapy (Review). Mol Clin Oncol. 2023;18(6):47. https://doi.org/10.3892/mco.2023.2643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Syeda WF, Sunil KK. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. J Control Release. 2022;341:555–65. https://doi.org/10.1016/j.jconrel.2021.12.013.

Article  CAS  Google Scholar 

Bhushan A, Gonsalves A, Menon JU. Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13050723.

Article  PubMed  PubMed Central  Google Scholar 

Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426–33. https://doi.org/10.1158/0008-5472.CAN-05-4489.

Article  CAS  PubMed  Google Scholar 

McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumor xenografts. Eur J Nucl Med Mol Imaging. 2009;36(1):81–93. https://doi.org/10.1007/s00259-008-0923-x.

Article  CAS  PubMed  Google Scholar 

Erickson HK, Gail D, Lewis P, Douglas DL, Carmela AP, Elaine M, Holly AJ, Bert G, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Molecular cancer therapeutics. 2012;11(5):1133–42.

Article  CAS  PubMed  Google Scholar 

Taylor DG. The political economics of cancer drug discovery and pricing. Drug Discov Today. 2020;25(12):2149–60. https://doi.org/10.1016/j.drudis.2020.09.007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hasan MM, Laws M, Jin P, Rahman KM. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates. Drug Discov Today. 2022;27(1):354–61. https://doi.org/10.1016/j.drudis.2021.09.015.

Article  CAS  PubMed  Google Scholar 

Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46. https://doi.org/10.1007/s13238-016-0323-0.

Article  CAS  PubMed  Google Scholar 

Conilh L, Sadilkova L, Viricel W, et al. Payload diversification: a key step in the development of antibody–drug conjugates. J Hematol Oncol. 2023;16(1):3. https://doi.org/10.1186/s13045-022-01397-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gal J, Milano G, Ferrero JM, Saâda-Bouzid E, Viotti J, Chabaud S, Gougis P, Le Tourneau C, Schiappa R, Paquet A, Chamorey E. Optimizing drug development in oncology by clinical trial simulation: Why and how? Brief Bioinform. 2018;19(6):1203–17. https://doi.org/10.1093/bib/bbx055.

Article  CAS  PubMed  Google Scholar 

Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers (Basel). 2023;15(3):713. https://doi.org/10.3390/cancers15030713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei Q, Li P, Yang T, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1. https://doi.org/10.1186/s13045-023-01509-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kiss B, Borbély J. Business risk mitigation in the development process of new monoclonal antibody drug conjugates for cancer treatment. Pharmaceutics. 2023;15(6):1761. https://doi.org/10.3390/pharmaceutics15061761.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuhmacher A, Gassmann O, Hinder M. Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016;14:1–11. https://doi.org/10.1186/s12967-016-0838-4.

Article  Google Scholar 

Hardison S. Oncology Dealmaking in 2020. [(accessed on 27 December 2022)];Biopharm. Deal. 2021 :B5. Available online: https://www.nature.com/articles/d43747-021-00024-y.

Rossi M, Thrassou A, Vrontis D. Biotechnological mergers and acquisitions: features, trends and new dynamics. J Res Market Entrep. 2015;17(1):91–109. https://doi.org/10.1108/JRME-07-2014-0013.

Article  Google Scholar 

Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules. 2021;26(19):5847. https://doi.org/10.3390/molecules26195847.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hingorani DV. An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio. Expert Opin Biol Ther. 2024;24(1–2):31–6. https://doi.org/10.1080/14712598.2024.2305266.

Article  CAS  PubMed  Google Scholar 

Thomas R. Consideration for the Safe and Effective Manufacturing of Antibody-drug Conjugates – ADC Review. J Antibody-Drug Conjugates. 2013.